Cogent Biosciences, Inc. (COGT) stock
Close on Nov 12, 2026Market cap $5.06BP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $5.06B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 9.79
- Dividend yield
- –
- Free cash flow yield
- -6.44%
Fundamentals
- Net income
- -$407.68M
- EPS, diluted
- -$2.32
- Free cash flow
- -$325.78M
- Book value per share
- $2.98
- Diluted shares
- 173M
Trading
- Next earnings
- Feb 16, 2027 (estimated, before the open)
- Previous close
- $29.40
- Open
- $29.01
- Day's range
- $28.61 – $29.78
- Volume
- 1,858,756
- Average volume (20 days)
- 2,185,785
- Index membership
- Russell 2000 (since Jun 2021), Russell 3000 (since Aug 2021)
- Beta (5 years)
- 0.65
- 52-week range
- $27.73 – $43.73
- RSI (14 days)
- 42.6
- Volatility (1 year)
- 46.3%
- Relative volume
- 0.91×
- WACC
- 8.1%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | COGT | S&P 500 | Difference | COGT per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -2.1% | -2.7% | +0.5 pts | ||
| 3 months | -25.2% | -1.7% | −23.5 pts | ||
| Year to date | -18.0% | +11.9% | −29.9 pts | ||
| 1 year | -17.4% | +12.0% | −29.3 pts | ||
| 3 years | +322.3% | +78.2% | +244.1 pts | +61.6% | +21.2% |
| 5 years | +177.5% | +73.2% | +104.3 pts | +22.6% | +11.6% |
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Cogent Biosciences filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- News
- Update
About Cogent Biosciences
Pharmaceutical Preparations
Cogent Biosciences, Inc. is a biotechnology company focused on discovering and developing therapeutic drug candidates. The company's principal development program centers on bezuclastinib, a targeted product candidate undergoing clinical trials, alongside several early-stage discovery and preclinical research programs. Cogent Biosciences designs its drug candidates to address specific clinical conditions, targeting patient populations in need of novel treatments. The company aims to provide its therapies to healthcare providers, physicians, patients, and third-party healthcare payors upon receiving necessary regulatory approvals.
Company profile, executives and historyCogent Biosciences stock: common questions
What is Cogent Biosciences's stock price?
COGT closed at $29.14 on Nov 12, 2026, down 0.88% on the day. Over the past 52 weeks it traded between $27.73 and $43.73.
What is Cogent Biosciences's market cap?
Cogent Biosciences was worth $5.06B at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
What is COGT's P/E ratio?
Cogent Biosciences lost money over the twelve months to Sep 30, 2026 (diluted EPS -$2.32), so it has no meaningful P/E ratio.
Does Cogent Biosciences pay a dividend?
No. Cogent Biosciences has not paid a cash dividend over the last twelve months.
When does Cogent Biosciences report earnings next?
Cogent Biosciences is expected to report Q4 FY2026 results on Feb 16, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has COGT stock performed over the past year?
Including dividends, COGT returned -17.4% over the past year, against +12.0% for the S&P 500.
How many COGT shares are sold short?
17M shares were sold short at the latest FINRA report, 11.10% of the float, or 8.7 days of average trading volume.
Who are Cogent Biosciences's competitors?
Companies most similar to Cogent Biosciences by business, industry and size include MSLE, OCS, JBIO, TNGX, PRLD.
See a number that looks wrong?